Bridging Innovation and Evidence in Non-Surgical Phimosis Treatment: Novoglan Medical Device Clinical Outcomes and Real-World Data

Presenting an evidence-based, non-surgical approach to treating adult phimosis—an increasingly relevant issue in both public and private urology settings. The Novoglan Medical Device is a conservative, foreskin-preserving treatment that aligns with the growing demand for less invasive, more patient-centric care.

The Novoglan treatment is a Class 1 medical device designed for gentle, controlled foreskin expansion through topical mechanical action. It is user-directed, discreet, and engineered for safe at-home use. Developed with input from urologists and biomedical engineers, the Novoglan device offers motivated patients who wish to preserve their foreskin, an effective alternative to circumcision.

To date, over 55,000 treatments have been delivered globally with zero reported adverse events, despite being subject to mandatory reporting requirements. These safety outcomes are unmatched in the field and underscore the device's reliability and tolerability across diverse populations.

Published independent clinical papers report a 90% success rate in achieving full or functional foreskin retractability in selected patients—establishing Novoglan as a viable and validated first-line treatment option. Furthermore, clinical follow-up data, including two-year post-treatment surveillance, has shown zero surgical interventions required among compliant patients.

The implications are significant. Pathological phimosis, if left untreated, can progress to chronic inflammation, infection, and complications including severe penile scarring. Early intervention with conservative therapies like Novoglan, particularly in younger men, can reduce these risks and preserve anatomical integrity. Importantly, the treatment is non-traumatic and respects patients’ psychological and cultural preferences around foreskin retention.

From a systemic perspective, Novoglan offers practical benefits for health services. Reducing unnecessary surgical referrals can ease the burden on public hospital waiting lists, while also freeing up valuable time in private practice for more complex urological cases. This realignment of resources benefits clinicians, institutions, and patients alike.

We are witnessing a broader shift in urology toward minimally invasive, foreskin-preserving interventions. Novoglan is well-positioned within this movement—offering not just an alternative, but a proven, safe, and effective solution grounded in long-term evidence and global clinical use.

In summary, the Novoglan Medical Device presents an opportunity to improve outcomes, reduce surgical demand, and provide dignified, conservative care to adult men with phimosis. We encourage you all, as urologists to consider validated alternatives and deliver tailored treatment pathways that reflect both science and patient needs.